IASLC

Stephen V Liu discusses KRAS mutant NSCLC with Veluswamy and Mariana Brandao – IASLC

International Association for the Study of Lung Cancer (IASLC) shared on X:

“KRAS mutations are common in lung cancer, and while there are multiple approved/active KRAS inhibitors, they are specifically for the G12C mutation. Stephen V Liu discusses KRAS mutant Non-Small Cell Lung Cancer (NSCLC) with focus on non-G12C mutations with Veluswamy and Mariana Brandao.”

Additional information.
Source: IASLC/X

cancer IASLC International Association for the Study of Lung Cancer (IASLC) KRAS G12C mutation Lung cancer Mariana Brandao non small cell lung cancer NSCLC OncoDaily Oncology Stephen V Liu Veluswamy